Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
WVE 
Wave Life Sciences Ltd (WVE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: WVE (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
13 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $20.19
1 Year Target Price $20.19
| 9 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -47.39% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.42B USD | Price to earnings Ratio - | 1Y Target Price 20.19 |
Price to earnings Ratio - | 1Y Target Price 20.19 | ||
Volume (30-day avg) 13 | Beta -0.96 | 52 Weeks Range 5.04 - 16.73 | Updated Date 08/15/2025 |
52 Weeks Range 5.04 - 16.73 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.8 |
Earnings Date
Report Date 2025-07-30 | When - | Estimate -0.27 | Actual -0.31 |
Profitability
Profit Margin -138.24% | Operating Margin (TTM) -606.5% |
Management Effectiveness
Return on Assets (TTM) -38.9% | Return on Equity (TTM) -171.41% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1231943113 | Price to Sales(TTM) 15.1 |
Enterprise Value 1231943113 | Price to Sales(TTM) 15.1 | ||
Enterprise Value to Revenue 13.11 | Enterprise Value to EBITDA -10.12 | Shares Outstanding 159227008 | Shares Floating 65471977 |
Shares Outstanding 159227008 | Shares Floating 65471977 | ||
Percent Insiders 15.87 | Percent Institutions 84.12 |
Upturn AI SWOT
Wave Life Sciences Ltd
Company Overview
History and Background
Wave Life Sciences Ltd. was founded in 2012, focusing on developing oligonucleotide therapeutics to treat genetically defined diseases. They have progressed through various clinical trials and partnerships, focusing on stereopure oligonucleotides.
Core Business Areas
- Genetic Medicines: Developing therapies targeting genetic drivers of disease, using stereopure oligonucleotides to optimize efficacy and minimize off-target effects.
- CNS Diseases: Focusing on central nervous system (CNS) disorders such as Huntington's disease and Duchenne muscular dystrophy.
- Discovery and Preclinical Research: Investing in novel therapeutic modalities and advanced chemistry to expand their pipeline.
Leadership and Structure
Paul Bolno is the President and CEO. The company has a typical biotech structure with departments for research, development, clinical trials, and commercial operations.
Top Products and Market Share
Key Offerings
- WVE-N531 (Suvodirsen): A stereopure phosphorodiamidate morpholino oligomer (PMO) targeting exon 53 skipping in Duchenne muscular dystrophy (DMD). Currently in clinical development. Competitors include Sarepta Therapeutics (SRPP) with their exon-skipping therapies.
- WVE-003: An AAT silencing oligonucleotide for alpha-1 antitrypsin deficiency (AATD). Currently in clinical development. Competitors include Arrowhead Pharmaceuticals (ARWR).
- WVE-301: A stereopure siRNA targeting mutant huntingtin (mHTT) mRNA for Huntington's disease. Currently in clinical development. Competitors include Roche (RHHBY) and its former partnership with Ionis Pharmaceuticals (IONS).
Market Dynamics
Industry Overview
The oligonucleotide therapeutics market is growing rapidly, driven by advancements in RNA technologies and increasing understanding of genetic diseases. There is a high unmet need for effective treatments for many genetic disorders.
Positioning
Wave Life Sciences focuses on stereopure oligonucleotides, aiming for improved efficacy and safety compared to traditional oligonucleotide therapies. They are positioning themselves as innovators in precision genetic medicine.
Total Addressable Market (TAM)
The oligonucleotide therapeutics market is projected to reach billions of dollars. Wave Life Sciences is targeting specific genetic diseases, each with a substantial patient population, but the TAM for each indication needs to be considered.
Upturn SWOT Analysis
Strengths
- Proprietary stereopure oligonucleotide platform
- Pipeline of clinical-stage programs
- Strong intellectual property position
- Experienced management team
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- High risk of clinical trial failures
- Dependence on partnerships for commercialization
- Cash burn
Opportunities
- Advancements in delivery technologies for oligonucleotides
- Expansion of target indications for their platform
- Potential for partnerships and collaborations
- Regulatory pathways that support expedited approval of gene therapies
Threats
- Competition from other oligonucleotide and gene therapy companies
- Unfavorable clinical trial results
- Regulatory hurdles and delays
- Patent challenges
Competitors and Market Share
Key Competitors
- IONS
- SRPT
- ARWR
Competitive Landscape
Wave's advantage is its stereopure oligonucleotide platform, potentially leading to higher efficacy and safety. Disadvantages include smaller size and limited resources compared to competitors.
Growth Trajectory and Initiatives
Historical Growth: Growth is largely dependent on the progression of their clinical programs and partnerships.
Future Projections: Analyst projections vary significantly and depend on the success of their clinical trials. It is very difficult to determine at this point in time.
Recent Initiatives: Focus on advancing clinical programs and expanding partnerships.
Summary
Wave Life Sciences is a clinical-stage biotech company with a focus on stereopure oligonucleotides. Success hinges on clinical trial outcomes. Strengths include the innovative platform, while weaknesses include financial constraints and competition. Investors must carefully monitor clinical trial results and regulatory updates.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Wave Life Sciences Ltd. Investor Relations
- SEC filings
- Analyst reports
- Company Press Releases
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data is approximate and based on available information, which may be limited. Investment decisions should be based on individual research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Wave Life Sciences Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2015-11-11 | President, CEO & Director Dr. Paul B. Bolno M.B.A., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 287 | Website https://wavelifesciences.com |
Full time employees 287 | Website https://wavelifesciences.com | ||
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, an RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-N531, an exon skipping oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.